TrialCurveJACOB (Chinese subgroup): reconstructed Kaplan–Meier curves
Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancer Commun (Lond). 2019 Jun 24;39:38. doi: 10.1186/s40880-019-0384-6 |
|---|---|
| DOI | 10.1186/s40880-019-0384-6 |
| Registry | NCT01774786 |
| Phase | Phase 3 |
| Conditions | Gastric Cancer |
| Interventions | 5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab |
| Sponsor | Hoffmann-La Roche |
| Enrolment | 780 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Chinese intention-to-treat subpopulation
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pertuzumab group not reached; Control group not reached. Survival at 6 months: Pertuzumab group 90%; Control group 85%. Hazard ratio Pertuzumab group vs Control group 0.73 (95% CI 0.45–1.17).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pertuzumab group | 82 | 31 | not reached |
| Control group | 81 | 38 | not reached |
- Pertuzumab group vs Control group: reconstructed HR 0.73 (95% CI 0.45–1.17)
Landmark survival (reconstructed)
| Time | Pertuzumab group | Control group |
|---|---|---|
| 3 mo | 96.3% | 93.8% |
| 6 mo | 90.2% | 85.0% |
| 9 mo | 81.5% | 77.5% |
| 12 mo | 72.9% | 66.3% |
| 15 mo | 64.9% | 54.0% |
Checks against the published figure
- hazard ratio: printed 0.75, reconstructed 0.728 pass
Progression-free survival (investigator-assessed) — Chinese intention-to-treat subpopulation
From figure panel b · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Control group 8.9 months; Pertuzumab group 10.6 months. Survival at 12 months: Control group 31%; Pertuzumab group 44%. Hazard ratio Pertuzumab group vs Control group 0.84 (95% CI 0.59–1.18).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Control group | 81 | 66 | 8.9 |
| Pertuzumab group | 82 | 70 | 10.6 |
- Pertuzumab group vs Control group: reconstructed HR 0.84 (95% CI 0.59–1.18)
Landmark survival (reconstructed)
| Time | Control group | Pertuzumab group |
|---|---|---|
| 6 mo | 71.8% | 79.7% |
| 12 mo | 30.8% | 43.7% |
| 18 mo | 14.6% | 23.1% |
| 24 mo | 11.6% | 13.1% |
Checks against the published figure
- hazard ratio: printed 0.85, reconstructed 0.838 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/jacob-chinese-subgroup-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/jacob-chinese-subgroup-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Cancer Commun (Lond). 2019 Jun 24;39:38. doi: 10.1186/s40880-019-0384-6 doi:10.1186/s40880-019-0384-6. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/jacob-chinese-subgroup
Report a problem with these data
Related trials
- ATTRACTION-2 (prior trastuzumab subgroup): Overall survival; Progression-free survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
- ATTRACTION-2 (2-year update): Overall survival; Progression-free survival
- KEYNOTE-590 (Japanese subgroup, extended follow-up): Overall survival; Progression-free survival
- ATTRACTION-2 (Japanese subgroup): Overall survival; Progression-free survival
- STARGATE: Overall survival; Progression-free survival (blinded central radiologic review)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials